CNS Pharmaceuticals, Inc. Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments
CNS Pharmaceuticals, Inc. (CNSP) reported Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Income Statement › Other Income
us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 · last filed 2020-03-12
- CNS Pharmaceuticals, Inc. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2019 was $0.00.
- CNS Pharmaceuticals, Inc. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2018 was -$122.12K.
| Period end | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 |
| 2018-12-31 | -$122.12K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |